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sealing the portal channel. Another role is
suggested by the difficulty in imagining
how tightly packaged DNA can be un-
wound from inside a capsid without be-
coming tangled. DNA is packaged by
a last-in, first-out process, and the termi-
nal sequences of several phage genomes
are known to be retained within the portal
channel (Agirrezabala et al., 2005; Jiang
et al., 2006; Lander et al., 2006; Xiang
et al., 2006). Thus, by holding on to the
end of the DNA, the portal may preposi-
tion it for efficient ejection. Zheng et al.
(2008) comment that in this way the con-
formational changes in the portal ‘‘directly
couple completion of virus morphogene-
sis to a new cycle of infection.’’
One interesting aspect of this study is
the demonstration that gp4 binding alone
can induce portal reconfiguration. This
appears to conflict with suggestions that
conformational changes in the portal
result from pressure exerted by the
fully packaged DNA (Agirrezabala et al.,
2005; Lander et al., 2006) and trigger sub-
sequent maturation steps including, in
P22, replacement of the terminase by
gp4. Given the sequence of events re-
quired to form a complete particle, it
seems probable that portal reconfigura-
tion does indeed precede gp4 binding
and that the situation seen here is a reflec-
tion of the altered environment occupied
by the portal when unconstrained by the
capsid.
Their combination of compositional
simplicity and functional complexity
makes bacteriophages objects of fascina-
tion to biologists, and this paper con-
tributes to our increasingly detailed
knowledge of these remarkable entities.
Nevertheless, as we continue to probe
their sophistication, the limitations of our
understanding remain apparent. Thus,
while snapshots of beginning and end
states create space for intellectual inven-
tion, we are still a long way from uncover-
ing the true nature of the molecular transi-
tions they reveal and of the forces that
drive them.
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An important report by Bryk et al. in this issue of Cell Host & Microbe describes the properties of a rhodanine
prodrug active against nonmultiplyingMycobacterium tuberculosis (Mtb). Considering the tolerance of non-
replicating Mtb to most currently available agents, such a drug could be a major addition to our antitubercu-
losis arsenal and would greatly benefit control of the disease.While effective vaccination to eliminate
latent tuberculosis (TB) is still distant, the
main avenue for its control is case finding
and treatment. Current treatment proto-
cols are lengthy, involving 6 months dur-
ing which it is only too easy for patients
to fail to continue regular drug taking.
Present efforts in improving treatment fo-
cus on shortening the length of treatment.122 Cell Host & Microbe 3, March 2008 ª20A question often asked is why does it
takes only a few days to kill actively grow-
ing cultures of Mtb, the casual agent of
TB, but 6 months or more to kill all the
bacilli in the lesions of patients? This cen-
tral problem has been studied since the
inception of Mtb chemotherapy in 1948
(Mitchison and Selkon, 1956). The expla-
nation lies in the difference between the08 Elsevier Inc.highly susceptible bacterial population in
an actively growing culture and the toler-
ant populations that are presumed to exist
in lesions in vivo. Phenotypic bacterial
tolerance is distinct from genetic drug
resistance since tolerant bacilli that revert
to rapid growth are susceptible to active
killing as usual. Therefore, it is vitally
important that drugs are developed to
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Previewstarget nonreplicating rather than actively
growing Mtb. The result of just such
a drug discovery effort is presented in
this issue of Cell Host & Microbe (Bryk
et al., 2008).
Dihydrolipoamide acyl transferase
(DlaT), anenzyme thatMtbuses tocounter
the stress of reactive nitrogen intermedi-
ates in the host, is necessary to establish
TB in guinea pigs. The authors use DlaT
as a target in a screen for potential antimy-
cobacterial compounds. Based on this
screen, a family of compounds called rho-
danines, particularly a compound desig-
nated D155931, was selected. To ensure
goodpenetration intophagosomes, apro-
drug designated D157070, which is an
ester of D155931, was chosen for further
study. D157070 had no effect on actively
growing cultures of Mtb or M. bovis,
BCG in laboratory medium. In contrast,
D157070 killed both Mtb and BCG in a va-
riety ofmedia that resembled human intra-
cellular fluid but do not allow for their
growth. The compound was found active
in a model of nonreplicating persistence,
which had the following characteristics:
(1) moderate hypoxia (1%O2), (2) replace-
ment of carbohydratewith butyrate, a fatty
acid as the carbon source, (3) mild acidity
at pH 5.5, and (4) low level nitrite. Finally,
D157070was actively bactericidal against
Mtb and BCG in murine bone marrow-
derived macrophages. Evidence that
D157070 acted by inhibition of DlaT was
obtained by measuring certain amino
acids, metabolites of pyruvate which ac-
cumulate upon deletion of DlaT, in lysates
of wild-type Mtb, DdlaT Mtb, or the DlaT
complemented mutant.
While inhibition of DlaT may be the
mode of action of D157070, this does
not explain why the compound is selec-
tive against only nonmultiplying bacteria.
The current drugs used in TB chemother-
apy have different properties on bacilli at
different stages, as they change from
their ability to multiply, even though
slowly, to nonmultiplying or dormant
states (Mitchison, 2000). Isoniazid kills
multiplying bacilli very rapidly but has
no effect against those that are nonmulti-
plying. Rifampicin kills actively growing
and nonmultiplying cells but fails to kill
when bacterial metabolism is very low.
Old cultures contain a proportion of bac-
teria that are highly tolerant to 100 mg/l
rifampicin. Pyrazinamide is the only
drug whose bactericidal activityincreases as multiplication is slowed
and bacterial metabolism winds down
(Zhang et al., 2002; Hu et al., 2006).
While almost as effective as rifampicin
in treatment, pyrazinamide’s activity is
limited to the initial 2 months of treatment
by the drug’s need for an acid bacillary
environment in order to be effective.
Such an acidic environment may be
present in sites of early active inflamma-
tion in cavities but not in the later healing
caseum. The active moiety of the pro-
drug pyrazinamide is pyrazinoic acid. It
accumulates in bacterial cells with low
metabolic activity because it enters by
passive diffusion but is only removed by
an inefficient MDR efflux pump which re-
quires energy (Zhang and Mitchison,
2003). The accumulation was increased
by reserpine, which is an inhibitor of ef-
flux pumps (Neyfakh et al., 1991), and
pyrazinoic acid eventually kills bacilli by
membrane damage. The activity of
D157070 was accelerated by verapamil,
also an inhibitor of efflux pumps (Bryk
et al., 2008; Bellamy, 1996). While this
was thought to arise from inhibition of
the efflux pumps of macrophages, it is
also possible that verapamil inhibited
the bacterial efflux pumps, since both re-
serpine and verapamil inhibit efflux
pumps in bacillus as well as in mamma-
lian cells (Neyfakh et al., 1991). Could it
be that both pyrazinamide and D157070
act by the same basic mechanism that
allows for their preferential accumulation
in nonmultiplying bacterial cells? In this
case, D157070 would be the key drug for
improving therapy by virtue of having the
properties of pyrazinamide without the re-
quirement for acidic pH to be effective.
While pyrazinamide is only slightly less
effective overall as a sterilizing drug than
rifampicin, it is only active in killing non-
multiplying bacteria for quite a brief period
during the initial phase of treatment.
D157070 would not be dependent on
acid environment and might therefore
continue to kill such bacteria throughout
treatment. The properties of such a drug
and its importance in the anti-TB drug
armamentarium has been previously dis-
cussed (Mitchison, 2004).
The broad issues concerning this work
are complex. The main model used by
the authors is complex, consisting of an
environment with low concentrations of
nitric oxide, high acidity, and a lipid
carbon source to mimic the supposedCell Host & Micenvironment within macrophage phago-
somes. The problem about this approach
is that the great majority of bacilli, and
those that must be killed by chemother-
apy, are extracellular and probably lie
far from macrophages with no exposure
to nitric oxide. The authors also showed
activity of D157070 in the Wayne hypoxic
model, a culturing regime that mimics
different stages of replicative persistence
by gradually reducing the concentration
of oxygen provided to cultures of Mtb
in liquid media. Furthermore, a very re-
cent paper describes the first examina-
tion of the gene expression state of
bacilli in sputum (Garton et al., 2008).
Unexpectedly, this report shows that
before antimycobacterial treatment is
started, bacilli are in a hypoxic state,
probably with slow or little multiplication,
with lipid as a carbon source for metab-
olism and with the dormancy (DosR) reg-
ulon, which constitutes proteins, thought
to be essential for the survival of bacteria
during persistence in vivo, as well as
other genes upregulated. The effect of
many environments, such as hypoxia,
nutrient starvation, and exposure to nitric
oxide, on Mtb gene expression has been
studied by microarray of Mtb in cultures.
It is clear that several different environ-
ments, including those in the phagosome
model, the Wayne model (both used by
Bryk et al. in their study), and the putative
environment in host cavities in vivo all re-
sult in upregulation of the DosR regulon
(Voskuil et al., 2003) in addition to numer-
ous other genes. The DosR regulon can
be upregulated by simple exposure to
anaerobic conditions within minutes,
and maybe it is this simple model that
should be used to investigate the proper-
ties of D157070 further and to find other
similar drugs.
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Host proteins, such as RNA-bindin
RNA viruses, including Tomato bu
Nagy report that efficient replicatio
and other functions. GAPDH binds
products, possibly by selectively re
Positive-strand RNA viruses have small
(4–30 kb) genomes with limited coding
capacity and depend on numerous host
functions for completing their life cycles.
For several positive-strand RNA viruses,
genome-wide screens have identified
hundreds of host genes that promote virus
replication (Cherry et al., 2005; Kushner
et al., 2003; Panavas et al., 2005). For
a larger set of positive-strandRNAviruses,
biochemical and genetic approaches
have implicated numerous cell-encoded
RNA-binding proteins in many steps of
positive-strand RNA viral infection (Ahl-
quist et al., 2003; Randall et al., 2007).
One cell protein that binds multiple viral
RNAs is glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH). First recognized
and named for its enzymatic role in glycol-
ysis, GAPDH also has distinct roles in
membrane fusion, apoptosis, microtubule
bundling, DNA replication and repair,
nuclear RNA export, and other processes
(Sirover, 1999). Through its N-terminal
nucleotide-binding domain, GAPDH also
binds cell RNAs and RNAs from a range
of diverse viruses. These include a nega-
tive-strand RNA virus, parainfluenza virus,
the reverse-transcribing hepatitis B virus,
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g proteins, are involved in most step
shy stunt virus (TBSV). In this issue o
n of TBSV requires GAPDH, a host pr
TBSV ()RNA and promotes the nor
taining ()RNA templates for copying
and two highly distinct positive-strand
RNA viruses, hepatitis A and C viruses
(Petrik et al., 1999; Sirover, 1999; Yi
et al., 2000). GAPDH binds the hepatitis
A virus internal ribosome entry site to
downregulate translation (Yi et al., 2000),
while knockdown of GAPDH inhibits
hepatitis C virus RNA and virion produc-
tion (Randall et al., 2007).
In this issue of Cell Host & Microbe,
Wang and Nagy show that GAPDHmakes
critical contributions to RNA replication
by another positive-strand RNA virus, to-
mato bushy stunt virus (TBSV), which is
a plant virus that can also replicate in
yeast cells (Wang and Nagy, 2008). The
current results of Wang and Nagy show
that GAPDH is important for TBSV repli-
cation both in yeast and a natural plant
host.
Previously, Serva and Nagy (2006)
reported that the yeast GAPDH orthologs
Tdh2/3p were among proteins that cop-
urified with Tomato bushy stunt virus
(TBSV) RNA replicase complexes from
yeast. Since GAPDH proteins are highly
abundant in yeast as in other cells, it is
easy to imagine that this might be due
to contamination. However, Wang and
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otein with glycolytic, RNA-binding,
mal excess of (+)RNA over ()RNA
.
Nagy now show that, in yeast cells ex-
pressing TBSV RNA replication proteins
p33 and p92pol and replicating a TBSV
RNA derivative, Tdh2p/GAPDH partially
relocalizes from the cytoplasm to the
modified peroxisomal membranes that
serve as sites of TBSV RNA replication
(Figure 1). Moreover, in yeast cells with
Tdh2p deleted, Tdh3p depletion using
a doxycycline-repressible promoter in-
hibits in vivo TBSV RNA replication and
the in vitro activity of TBSV replicase
extracts in parallel. Similarly, in the plant
host Nicotiana benthamiana, replication
by TBSV and the closely related cucum-
ber necrosis virus (CNV) is strongly
inhibited when GAPDH expression is
knocked down by RNA interference. This
inhibition of TBSV and CNV is specific,
since the distantly related tobacco mo-
saic virus replicates to normal levels in
these plants after GAPDH knockdown.
How is GAPDH involved in TBSV repli-
cation? Interestingly, depleting GAPDH
preferentially inhibits the accumulation
of TBSV positive-strand RNA, with little
effect on negative-strand RNA. Moreover,
GAPDH selectively binds in vitro to TBSV
negative-strand RNA over positive-strand
